Multi-electrode Radiofrequency Balloon Catheter Use for the Isolation of the Pulmonary Veins.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-28

Study Completion Date

2019-10-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical investigation is a prospective, multicenter, single arm clinical evaluation utilizing the multi-electrode radiofrequency balloon catheter and the multi-electrode circular diagnostic catheter.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multicenter Registry of Atrial Fibrillation Ablation With Radiofrequency Balloon Catheter

NCT06333327

Atrial Fibrillation

RECRUITING

Using a Novel Balloon-shaped Large-Focal Pulsed Field Ablation Catheter in Persistent Atrial Fibrillation

NCT07294742

Persistent Atrial Fibrillation

ACTIVE_NOT_RECRUITING NA

Pulmonary Vein Isolation With the Single Shot Endoscopic Ultra-Compliant PFA Balloon for the Treatment of AF

NCT06828939

Atrial Fibrillation (Paroxysmal)

RECRUITING NA

Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation

NCT03683030

Atrial Fibrillation

COMPLETED PHASE3

Assessment of Pulmonary Vein Isolation Using a Balloon Catheter With Pulsed Field Energy in Atrial Fibrillation

NCT07156877

Atrial Fibrillation (AF)

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this clinical investigation is to assess the safety and acute effectiveness of the multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter when used for the isolation of the pulmonary veins in the treatment of Paroxysmal Atrial Fibrillation (PAF).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paroxysmal Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter

Group Type EXPERIMENTAL

Radiofrequency Ablation

Intervention Type DEVICE

RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiofrequency Ablation

RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed with Symptomatic Paroxysmal AF.
2. Selected for atrial fibrillation (AF) ablation procedure for pulmonary vein isolation.
3. Able and willing to comply with uninterrupted per-protocol anticoagulation requirements
4. Age 18-75 years.
5. Able and willing to comply with all pre-, post- and follow-up testing and requirements.
6. Signed Patient Informed Consent Form.

Exclusion Criteria

1. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
2. Previous surgical or catheter ablation for AF.
3. Anticipated to receive ablation outside the PV ostia and Cavo-triscuspid-isthmus (CTI) region
4. Previously diagnosed with persistent, longstanding AF and/or continuous AF \> 7 days, or \> 48 hrs terminated by cardioversion.
5. Any percutaneous coronary intervention (PCI) within the past 2 months.
6. Valve repair or replacement and presence of a prosthetic valve.
7. Any carotid stenting or endarterectomy.
8. Coronary artery bypass grafting (CABG), cardiac surgery (e.g. ventriculotomy, atriotomy), or valvular cardiac surgical or percutaneous procedure within the past 6 months.
9. Documented left atrium (LA) thrombus on baseline/pre-procedure imaging.
10. LA antero posterior diameter \> 50 mm
11. Any PV with a diameter ≥ 26 mm
12. Left Ventricular Ejection Fraction (LVEF) \< 40%.
13. Contraindication to anticoagulation (e.g. heparin).
14. History of blood clotting or bleeding abnormalities.
15. Myocardial infarction within the past 2 months.
16. Documented thromboembolic event \[including transient ischemic attack(TIA)\] within the past 12 months.
17. Rheumatic Heart Disease.
18. Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV.
19. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months.
20. Unstable angina.
21. Acute illness or active systemic infection or sepsis.
22. Diagnosed atrial myxoma or interatrial baffle or patch.
23. Presence of implanted pacemaker or implantable cardioverter defibrillator (ICD).
24. Significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
25. Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in this study.
26. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation.
27. Enrollment in an investigational study evaluating another device, biologic, or drug.
28. Has known pulmonary vein stenosis.
29. Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter.
30. Presence of an Inferior Vena Cava (IVC) filter
31. Presence of a condition that precludes vascular access.
32. Life expectancy or other disease processes likely to limit survival to less than 12 months.
33. Presenting contra-indication for the devices (e.g. transthoracic echocardiography (TTE), CT, etc.) used in the study, as indicated in the respective instructions for use.
34. Categorized as a vulnerable population and requires special treatment with respect to safeguards of well-being

35. Contraindication to use of contrast agents for MRI such as advanced renal disease, etc. (at PI discretion)
36. Presence of iron-containing metal fragments in the body
37. Unresolved pre-existing neurological deficit.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No